Poitiers University Hospital

This phase 3 study tests whether adding the drug isatuximab to a standard two-drug regimen (lenalidomide and dexamethasone) works better with or without a third drug (bortezomib) for newly diagnosed multiple myeloma. The study includes 270 non-frail patients aged 65 to 79 who are…

This study looks at how well and how safely the drug bevacizumab works for people with hereditary hemorrhagic telangiectasia (HHT) who have severe liver issues causing high heart output and possible heart failure. Researchers will check heart function before and after 6 months of…

This study tests whether slowly reducing the dose of tyrosine kinase inhibitor (TKI) medication over 12 months helps more chronic myeloid leukemia (CML) patients stop treatment entirely without the cancer returning. About 170 adults with stable CML will be randomly assigned to ei…

This study tests a new way to give the drug isatuximab as a quick shot under the skin, instead of a long IV drip, for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The treatment combines isatuximab with three standard chemotherapy drugs (bor…